Therapiekonzepte des fortgeschrittenen Lungenkarzinoms im Stadium IV

Was ist neu?

Immunonkologische Monotherapie des nichtkleinzelligen Lungenkarzinoms 5-Jahres-Überlebensdaten der KEYNOTE-024-Studie bestätigen die anhaltende Wirksamkeit einer immunonkologischen Monotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) mit hoher PD-L1-Expression (≥ 50 %).

Duale Immuntherapie in Kombination mit Chemotherapie als Erstlinientherapie des nichtkleinzelligen Lungenkarzinoms Nivolumab plus Impilimumab in Kombination mit 2 Zyklen platinhaltiger Chemotherapie verbessern das Überleben von NSCLC-Patienten.

Neue Targets und Therapieoptionen Entrectinib und Larotrectinib mit Wirksamkeit bei NTRK-Fusions-positivem NSCLC. Selpercatinib und Pralsetinib mit Wirksamkeit bei RET-Fusions-positivem NSCLC. Mobocertinib mit Wirksamkeit bei EGFRex20ins-Mutation des EGFR-Gens. Sotorasib mit Wirksamkeit bei kRAS-G12C-Mutation des NSCLC.

Nationales Netzwerk Genomische Medizin Lungenkrebs Das bundesweite Nationale Netzwerk Genomische Medizin Lungenkrebs (nNGM) ermöglicht NSCLC-Patienten den Zugang zu modernster molekularer Diagnostik und neuesten Therapieoptionen.

Abstract

Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (≥ 50 %).

Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients.

Novel targets and treatment options Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC.

National Network Genomic Medicine Lung Cancer (nNGM) The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.

Schlüsselwörter

Immuntherapie - zielgerichtete Therapie - Nationales Netzwerk Genomische Medizin Lungenkrebs

Key words

immunotherapy - targeted therapy - National Network Genomic Medicine Lung Cancer

Publication History

Article published online:
22 September 2021

• Literatur

• 1 Reck M, Rodríguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833
• 2 Reck M, Rodríguez-Abreu D, Robinson AG. et al Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol 2021; JCO2100174.
• 3 Herbst RS, Giaccone G, de Marinis F. et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med 2020; 383: 1328-1339
• 4 Paz-Ares L, Ciuleanu TE, Cobo M. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198-211
• 5 Doebele RC, Drilon A, Paz-Ares L. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271-282
• 6 Hong DS, DuBois SG, Kummar S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21: 531-540
• 7 Drilon A, Oxnard GR, Tan DSW. et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383: 813-824
• 8 Riely GJ, Neal JW, Camidge DR. et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discov 2021;
• 9 Canon J, Rex K, Saiki AY. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019; 575: 217-223
• 10 Li BT, Skoulidis F, Falchook G. et al CodeBreaK 100: registrational phase 2 trial of sotorasib in KRAS p.G12C mutated non-small cell lung cancer. 22nd World Conference on Lung Cancer 2020 Jan 28–31; 2021: Abstract PS01.07